Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lung Diseases 1Liposarcoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × sitravatinib × Clear all
NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
37 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡